Abstract
We propose establishing private and public outpatient facilities where persons with human immunodeficiency virus, type 1 (HIV-1), infection can receive state-of-the-art clinical and behavioral follow-up, treatment and assistance. The possible advantages of enrolling HIV-1-positive persons into long-term follow-up are early treatment of clinical conditions and resulting gains in life quality and life expenctancy, decreased transmission of HIV-1 to uninfected persons, more efficient use of scarce patient-care resources, and improved estimates of the total number of HIV-infected persons. The possible disadvantages of such a program are adverse psychological reactions to knowledge of HIV-1 infection, adverse societal actions against infected persons, and, finally, the economic cost of the program. These facilities, with the proper expertise and safeguards of confidentiality and trust, could prolong and improve the lives of infected persons while preventing infection of others.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2572-2576 |
| Number of pages | 5 |
| Journal | Journal of the American Medical Association |
| Volume | 262 |
| Issue number | 18 |
| State | Published - 1989 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Targeting AIDS prevention and treatment toward HIV-1-infected persons. The concept of early intervention. / Francis, D. P.; Anderson, R. E.; Gorman, M. E.; Fenstersheib, M.; Padian, N. S.; Kizer, Kenneth W; Conant, M. A.
In: Journal of the American Medical Association, Vol. 262, No. 18, 1989, p. 2572-2576.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Targeting AIDS prevention and treatment toward HIV-1-infected persons. The concept of early intervention
AU - Francis, D. P.
AU - Anderson, R. E.
AU - Gorman, M. E.
AU - Fenstersheib, M.
AU - Padian, N. S.
AU - Kizer, Kenneth W
AU - Conant, M. A.
PY - 1989
Y1 - 1989
N2 - We propose establishing private and public outpatient facilities where persons with human immunodeficiency virus, type 1 (HIV-1), infection can receive state-of-the-art clinical and behavioral follow-up, treatment and assistance. The possible advantages of enrolling HIV-1-positive persons into long-term follow-up are early treatment of clinical conditions and resulting gains in life quality and life expenctancy, decreased transmission of HIV-1 to uninfected persons, more efficient use of scarce patient-care resources, and improved estimates of the total number of HIV-infected persons. The possible disadvantages of such a program are adverse psychological reactions to knowledge of HIV-1 infection, adverse societal actions against infected persons, and, finally, the economic cost of the program. These facilities, with the proper expertise and safeguards of confidentiality and trust, could prolong and improve the lives of infected persons while preventing infection of others.
AB - We propose establishing private and public outpatient facilities where persons with human immunodeficiency virus, type 1 (HIV-1), infection can receive state-of-the-art clinical and behavioral follow-up, treatment and assistance. The possible advantages of enrolling HIV-1-positive persons into long-term follow-up are early treatment of clinical conditions and resulting gains in life quality and life expenctancy, decreased transmission of HIV-1 to uninfected persons, more efficient use of scarce patient-care resources, and improved estimates of the total number of HIV-infected persons. The possible disadvantages of such a program are adverse psychological reactions to knowledge of HIV-1 infection, adverse societal actions against infected persons, and, finally, the economic cost of the program. These facilities, with the proper expertise and safeguards of confidentiality and trust, could prolong and improve the lives of infected persons while preventing infection of others.
UR - http://www.scopus.com/inward/record.url?scp=0024414344&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024414344&partnerID=8YFLogxK
M3 - Article
C2 - 2810584
AN - SCOPUS:0024414344
VL - 262
SP - 2572
EP - 2576
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
SN - 0002-9955
IS - 18
ER -